<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244127</url>
  </required_header>
  <id_info>
    <org_study_id>Myocet 018</org_study_id>
    <secondary_id>The MYOCAN Study</secondary_id>
    <nct_id>NCT00244127</nct_id>
  </id_info>
  <brief_title>Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.</brief_title>
  <official_title>Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeneus Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeneus Pharma</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive&#xD;
      NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the&#xD;
      R-CHOP regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in&#xD;
      first line therapy of elderly patients with advanced aggressive NHL.&#xD;
&#xD;
      To evaluate the tolerability of R-COMP in first line therapy of elderly patients with&#xD;
      advanced aggressive NHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <enrollment>75</enrollment>
  <condition>Aggressive Non-Hodgkin's Lymphoma in the Elderly.</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, oncovin, myocet, prednisone &amp; rituximab (R-COMP)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diffuse Large B-Cell Lymphoma (DLBCL), and their morphologic variants and subtypes,&#xD;
             i.e. Centroblastic lymphoma, Immunoblastic lymphoma, T-cell rich/B-cell lymphoma,&#xD;
             anaplastic large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma;&#xD;
&#xD;
          -  Primary diffuse large B-cell lymphoma of MALT (incorrectly defined as high-grade MALT&#xD;
             lymphoma);&#xD;
&#xD;
          -  Marginal zone B-cell lymphoma with coexisting areas of DLBCL;&#xD;
&#xD;
          -  Age of ≥60 years;&#xD;
&#xD;
          -  Clinical stage at diagnosis: I A bulky - IV B;&#xD;
&#xD;
          -  CD20 positivity;&#xD;
&#xD;
          -  Serum negativity for HbsAg and HCV except for those with no sign of active viral&#xD;
             replication, assessed by HCV-RNA copies;&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5x109/L, and platelet count ≥100x109/L (unless both&#xD;
             are attributed directly to bone marrow involvement by lymphoma or auto-immune disease&#xD;
             secondary to lymphoma);&#xD;
&#xD;
          -  Serum creatinine ≤130μM/L, serum bilirubin ≤2.5xULN aspartate amino-transferase&#xD;
             (AST/GOT), ≤2.5xULN alanine amino-transferase (ALT/GPT) ≤2.5xULN, and alkaline&#xD;
             phosphatase ≤4 times the upper limit of normal (unless the increase is attributed&#xD;
             directly to the presence of tumour by the Investigator)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50%;&#xD;
&#xD;
          -  ECOG performance status 0-2;&#xD;
&#xD;
          -  At least one measurable lesion is mandatory;&#xD;
&#xD;
          -  Written informed consent given at time of registration;&#xD;
&#xD;
          -  Males and females (both males and females of childbearing potential must agree to use&#xD;
             adequate contraception for the duration, and for 3 months after the completion, of the&#xD;
             treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical stage I non-bulky, or CS IIA with less than three sites of disease involved&#xD;
             (patients with stage IIB are eligible, regardless of the number of sites involved);&#xD;
&#xD;
          -  Tumour involvement of CNS;&#xD;
&#xD;
          -  Indolent lymphoma transformed in more aggressive histological type, even if never&#xD;
             previously treated;&#xD;
&#xD;
          -  Mantle Cell Lymphoma, Peripheral T cell Lymphoma and their variants;&#xD;
&#xD;
          -  Aggressive non-Hodgkin's lymphoma in transplanted patient;&#xD;
&#xD;
          -  Clinically significant secondary cardiovascular disease, e.g. uncontrolled&#xD;
             hypertension, (resting diastolic blood pressure &gt;115 mmHg), uncontrolled multifocal&#xD;
             cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA&#xD;
             class III-IV;&#xD;
&#xD;
          -  Evidence of any severe active acute or chronic infection;&#xD;
&#xD;
          -  Concurrent malignancy or history of other malignancy, except basal cell carcinoma of&#xD;
             the skin (BCC) and in-situ cervical carcinoma (CIN) / Myelodysplastic syndrome;&#xD;
&#xD;
          -  HbsAg, HIV-positive, or HCV-RNA-positive patients;&#xD;
&#xD;
          -  Inability to comply with study procedures;&#xD;
&#xD;
          -  Prior CNS lymphoma;&#xD;
&#xD;
          -  Prior radiation to non-CNS lymphoma mass(es) as a treatment for lymphomas;&#xD;
&#xD;
          -  History of allergic reaction to anthracyclines, eggs, and egg products or known&#xD;
             sensitivities, or history of unusual reaction, to other components of, or treatments&#xD;
             similar to, the investigational treatment regimen;&#xD;
&#xD;
          -  Presence of other medication that may interfere with study treatment or the action of&#xD;
             the investigational product or confuse the assessment of study results&#xD;
&#xD;
          -  Pregnant women or nursing mothers;&#xD;
&#xD;
          -  Participation in an investigational drug study within 4 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Federico</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita Degli Studi di Modena</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Modena AZ Ospedaliere Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>October 24, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2005</study_first_posted>
  <last_update_submitted>October 26, 2005</last_update_submitted>
  <last_update_submitted_qc>October 26, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

